- News Home
6 March 2014 1:04 pm ,
Vol. 343 ,
Since 2000, U.S. government health research agencies have spent almost $1 billion on an effort to churn out thousands...
Magdalena Koziol, a former postdoc at Yale University, was the victim of scientific sabotage. Now, she is suing the...
Antiretroviral drugs can protect people from becoming infected by HIV. But so-called pre-exposure prophylaxis, or PrEP...
Two studies show that eating a diet low in protein and high in carbohydrates is linked to a longer, healthier life, and...
Considered an icon of conservation science, researchers at World Wildlife Fund (WWF) headquarters in Washington, D.C.,...
The new atlas, which shows the distribution of important trace metals and other substances, is the first product of...
Early in April, the first of a fleet of environmental monitoring satellites will lift off from Europe's spaceport in...
- 6 March 2014 1:04 pm , Vol. 343 , #6175
- About Us
Another Supreme Review of Human Gene Patents
30 November 2012 5:38 pm
In a terse note this afternoon, the U.S. Supreme Court gave notice that it will once again consider the long debated question of whether human genes can be patented. The court granted certiorari to a group of plaintiffs who argue that patents on the breast cancer genes BRCA1 and BRCA2, which are owned by the diagnostic company Myriad Genetics of Salt Lake City, should be declared invalid. The case was filed on behalf of a clinician who wanted to test patients for these cancer genes without taking out a license from the company.
It is the second time the Supreme Court will examine the issue, having sent it to a lower court for reconsideration. That court did not agree with the plaintiffs, who have appealed successfully. The Supreme Court has said it will consider only one key question—whether the human genes in this dispute are "patent-eligible" material.